Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities

Deficiency of adenosine deaminase 2 (DADA2) is a complex monogenic disease caused by recessive mutations in the ADA2 gene. DADA2 exhibits a broad clinical spectrum encompassing vasculitis, immunodeficiency, and hematological abnormalities. Yet, the impact of DADA2 on the bone marrow (BM) microenviro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2024-09
Main Authors: Bulté, Dimitri, Barzaghi, Federica, Mesa-Nuñez, Cristina, Rigamonti, Chiara, Basso-Ricci, Luca, Visconti, Camilla, Crippa, Stefania, Pettinato, Emanuela, Gilioli, Diego, Milani, Raffaella, Quaranta, Pamela, Caorsi, Roberta, Cafaro, Alessia, Cangemi, Giuliana, Lupia, Michela, Schena, Francesca, Grossi, Alice, Di Colo, Giulia, Federici, Silvia, Insalaco, Antonella, De Benedetti, Fabrizio, Marktel, Sarah, Di Micco, Raffaella, Bernardo, Maria Ester, Scala, Serena, Cicalese, Maria Pia, Conti, Francesca, Miano, Maurizio, Gattorno, Marco, Dufour, Carlo, Aiuti, Alessandro, Mortellaro, Alessandra
Format: Article
Language:English
Subjects:
adenosine deaminase 2 deficiency
bone marrow
bone marrow failure
cytopenia
hematopoietic stem cell transplantation
mesenchymal stroma cells
senescence
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Deficiency of adenosine deaminase 2 (DADA2) is a complex monogenic disease caused by recessive mutations in the ADA2 gene. DADA2 exhibits a broad clinical spectrum encompassing vasculitis, immunodeficiency, and hematological abnormalities. Yet, the impact of DADA2 on the bone marrow (BM) microenvironment is largely unexplored. This study comprehensively examined the BM and peripheral blood of pediatric and adult patients with DADA2 presenting rheumatologic/immunologic symptoms or severe hematological manifestations. Immunophenotyping of hematopoietic stem cells (HSCs), progenitor cells, and mature cell populations was performed for 18 patients with DADA2. We also conducted a characterization of the mesenchymal stromal cells (MSCs). Our study revealed a significant decrease in primitive HSCs and progenitor cells, alongside their reduced clonogenic capacity and multilineage differentiation potential. These BM defects were evident in patients with both severe and non-severe hematological manifestations, including pediatric patients, demonstrating that BM disruption can emerge silently and early on, even in patients who do not show obvious hematological symptoms. Beyond stem cells, there was a reduction in mature cell populations in the BM and peripheral blood, affecting myeloid, erythroid, and lymphoid populations. Furthermore, BM MSCs in DADA2 patients exhibited reduced clonogenic and proliferation capabilities and were more prone to undergo cellular senescence marked by elevated DNA damage. Our exploration into the BM landscape of DADA2 patients sheds light on the critical hematological dimension of the disease and emphasizes the importance of vigilant monitoring, even in the case of subclinical presentation.
ISSN:0091-6749
1097-6825
1097-6825
DOI:10.1016/j.jaci.2024.09.007